Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis

Figure 1

Markov model simulating the progression of a cohort of patients with moderate-to-severe ulcerative colitis, who are corticosteroid-dependent or refractory to thiopurines, in situations where adalimumab is readily available compared to situations when it is unavailable.